Quest Diagnostics Incorporated DGX
- Market cap
- $26.2B
- P/E
- 24.8×
Follow DGX
Quest Diagnostics Incorporated (DGX) Return on assets
Quest Diagnostics Incorporated's return on assets over the twelve months to 30 June 2026 was 6.43%, up 0.3 percentage points from fiscal 2025 (6.10%). Over the past ten years it has ranged from 5.74% (fiscal 2024) to 14.4% (fiscal 2021); the current reading is higher than 18% of that period. That is above the Diagnostics & Research industry median of −6.71% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 6.10% | 0.36 |
| FY2024 | 5.74% | (0.59) |
| FY2023 | 6.33% | (0.79) |
| FY2022 | 7.12% | (7.27) |
| FY2021 | 14.4% | 3.78 |
| FY2020 | 10.6% | 3.41 |
| FY2019 | 7.20% | 0.36 |
| FY2018 | 6.84% | (0.65) |
| FY2017 | 7.49% | 1.09 |
| FY2016 | 6.40% | (0.72) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 33.7% |
| MEDP Medpace Holdings, Inc. compare | 27.1% |
| MTD Mettler-Toledo International, Inc. compare | 25.6% |
| ILMN Illumina, Inc. compare | 13.0% |
| DGX Quest Diagnostics Incorporated | 6.43% |
| LH Labcorp Holdings Inc. compare | 5.48% |
| RVTY Revvity Inc. compare | 1.95% |
| WAT Waters Corporation compare | 1.13% |
| GH Guardant Health, Inc. compare | −28.0% |
| Diagnostics & Research industry median | −6.71% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on DGX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement